FDA Authorizes Stanza to Treat Fibromyalgia Symptoms

This week, Swing Therapeutics received De Novo marketing authorization by the U.S. Food and Drug Administration (FDA) for Stanza, the first prescription digital therapeutic for treating fibromyalgia symptoms. This represents a major milestone both for our company and the fibromyalgia patients we serve, and is a big step towards meaningfully addressing patient access barriers by …